{"id":65057,"date":"2026-05-12T15:06:22","date_gmt":"2026-05-12T07:06:22","guid":{"rendered":"https:\/\/flcube.com\/?p=65057"},"modified":"2026-05-12T15:06:23","modified_gmt":"2026-05-12T07:06:23","slug":"china-medical-system-secures-exclusive-china-rights-to-pharmacosmos-monofer-and-cosmofer-iv-iron-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65057","title":{"rendered":"China Medical System Secures Exclusive China Rights to Pharmacosmos&#8217; MonoFer and CosmoFer IV Iron Therapies"},"content":{"rendered":"\n<p><strong>China Medical System Holdings Limited<\/strong> (CMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>) announced an exclusive licensing agreement with <strong>Denmark-based Pharmacosmos A\/S<\/strong> for the commercialization of <strong>MonoFer (iron isomaltoside)<\/strong> and <strong>CosmoFer (iron dextran)<\/strong> in <strong>mainland China<\/strong>. The deal grants CMS exclusive rights to two generations of intravenous iron products, both featuring single high-dose administration capabilities and strong reimbursement positioning in China&#8217;s healthcare system.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-framework\">Transaction Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Pharmacosmos A\/S (Denmark)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>China Medical System Holdings Limited (HKG: 0867)<\/td><\/tr><tr><td><strong>Assets<\/strong><\/td><td>MonoFer (iron isomaltoside) and CosmoFer (iron dextran)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Exclusive rights for mainland China<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Both products approved and commercially available in China<\/td><\/tr><tr><td><strong>Reimbursement<\/strong><\/td><td>MonoFer: NRDL 2023; CosmoFer: NRDL Category A + National Essential Medicines List<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-portfolio-amp-innovation\">Product Portfolio &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MonoFer (Third-Generation):<\/strong><\/li>\n\n\n\n<li>First third-generation IV iron approved in China<\/li>\n\n\n\n<li>Innovative stable matrix-based nanostructure with improved safety profile<\/li>\n\n\n\n<li>Single high-dose complete iron replacement capability<\/li>\n\n\n\n<li>Faster hemoglobin elevation and reduced infusion frequency<\/li>\n\n\n\n<li>NRDL inclusion since 2023<\/li>\n\n\n\n<li><strong>CosmoFer (Second-Generation):<\/strong><\/li>\n\n\n\n<li>Low molecular weight iron dextran injection approved since 2003<\/li>\n\n\n\n<li>Single high-dose complete iron replacement capability<\/li>\n\n\n\n<li>Only IV iron product with NRDL Category A status<\/li>\n\n\n\n<li>Only IV iron included in National Essential Medicines List<\/li>\n\n\n\n<li>Indicated for patients intolerant or unresponsive to oral iron therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Leadership<\/strong><\/td><td>CMS now controls China&#8217;s most comprehensive IV iron portfolio with dual-generation coverage<\/td><\/tr><tr><td><strong>Reimbursement Advantage<\/strong><\/td><td>Unmatched reimbursement positioning with both NRDL inclusion and Essential Medicines List status<\/td><\/tr><tr><td><strong>Clinical Differentiation<\/strong><\/td><td>Single high-dose administration addresses key clinical pain points: reduced hospital visits, improved patient compliance<\/td><\/tr><tr><td><strong>Therapeutic Gap<\/strong><\/td><td>Addresses China&#8217;s significant iron deficiency burden affecting ~200 million people, particularly women and elderly<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The acquisition strengthens CMS&#8217;s position in China&#8217;s growing IV iron market, estimated at RMB 3\u20134 billion annually, while providing Pharmacosmos with enhanced commercial reach through a well-established local partner.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Iron Deficiency Burden<\/strong> | China faces one of the world&#8217;s highest iron deficiency rates, with limited treatment options beyond oral supplements<\/li>\n\n\n\n<li><strong>Hospital Market Access<\/strong> | CMS&#8217;s extensive hospital sales force provides immediate access to key prescribers in oncology, nephrology, and gynecology<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong> | Dual-product strategy creates comprehensive coverage across price points and clinical scenarios<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> | Combined peak sales potential of RMB 800 million\u20131.2 billion ($110\u2013165 million) annually<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong> | Validates CMS&#8217;s strategy of acquiring differentiated specialty products with strong reimbursement positioning<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, market opportunities, and commercial expectations for MonoFer and CosmoFer in China. Actual results may differ due to risks including competitive dynamics, pricing pressures, market adoption rates, and changes in reimbursement policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[325,844,4737],"class_list":["post-65057","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-china-medical-system","tag-hkg-0867","tag-pharmacosmos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Medical System Secures Exclusive China Rights to Pharmacosmos&#039; MonoFer and CosmoFer IV Iron Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based Pharmacosmos A\/S for the commercialization of MonoFer (iron isomaltoside) and CosmoFer (iron dextran) in mainland China. The deal grants CMS exclusive rights to two generations of intravenous iron products, both featuring single high-dose administration capabilities and strong reimbursement positioning in China&#039;s healthcare system.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65057\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System Secures Exclusive China Rights to Pharmacosmos&#039; MonoFer and CosmoFer IV Iron Therapies\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based Pharmacosmos A\/S for the commercialization of MonoFer (iron isomaltoside) and CosmoFer (iron dextran) in mainland China. The deal grants CMS exclusive rights to two generations of intravenous iron products, both featuring single high-dose administration capabilities and strong reimbursement positioning in China&#039;s healthcare system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65057\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T07:06:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T07:06:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65057#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65057\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System Secures Exclusive China Rights to Pharmacosmos&#8217; MonoFer and CosmoFer IV Iron Therapies\",\"datePublished\":\"2026-05-12T07:06:22+00:00\",\"dateModified\":\"2026-05-12T07:06:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65057\"},\"wordCount\":432,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Medical System\",\"HKG: 0867\",\"Pharmacosmos\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65057#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65057\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65057\",\"name\":\"China Medical System Secures Exclusive China Rights to Pharmacosmos' MonoFer and CosmoFer IV Iron Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-12T07:06:22+00:00\",\"dateModified\":\"2026-05-12T07:06:23+00:00\",\"description\":\"China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based Pharmacosmos A\\\/S for the commercialization of MonoFer (iron isomaltoside) and CosmoFer (iron dextran) in mainland China. The deal grants CMS exclusive rights to two generations of intravenous iron products, both featuring single high-dose administration capabilities and strong reimbursement positioning in China's healthcare system.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65057#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65057\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65057#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System Secures Exclusive China Rights to Pharmacosmos&#8217; MonoFer and CosmoFer IV Iron Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System Secures Exclusive China Rights to Pharmacosmos' MonoFer and CosmoFer IV Iron Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based Pharmacosmos A\/S for the commercialization of MonoFer (iron isomaltoside) and CosmoFer (iron dextran) in mainland China. The deal grants CMS exclusive rights to two generations of intravenous iron products, both featuring single high-dose administration capabilities and strong reimbursement positioning in China's healthcare system.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65057","og_locale":"en_US","og_type":"article","og_title":"China Medical System Secures Exclusive China Rights to Pharmacosmos' MonoFer and CosmoFer IV Iron Therapies","og_description":"China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based Pharmacosmos A\/S for the commercialization of MonoFer (iron isomaltoside) and CosmoFer (iron dextran) in mainland China. The deal grants CMS exclusive rights to two generations of intravenous iron products, both featuring single high-dose administration capabilities and strong reimbursement positioning in China's healthcare system.","og_url":"https:\/\/flcube.com\/?p=65057","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T07:06:22+00:00","article_modified_time":"2026-05-12T07:06:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65057#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65057"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System Secures Exclusive China Rights to Pharmacosmos&#8217; MonoFer and CosmoFer IV Iron Therapies","datePublished":"2026-05-12T07:06:22+00:00","dateModified":"2026-05-12T07:06:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65057"},"wordCount":432,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Medical System","HKG: 0867","Pharmacosmos"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65057#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65057","url":"https:\/\/flcube.com\/?p=65057","name":"China Medical System Secures Exclusive China Rights to Pharmacosmos' MonoFer and CosmoFer IV Iron Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-12T07:06:22+00:00","dateModified":"2026-05-12T07:06:23+00:00","description":"China Medical System Holdings Limited (CMS, HKG: 0867) announced an exclusive licensing agreement with Denmark-based Pharmacosmos A\/S for the commercialization of MonoFer (iron isomaltoside) and CosmoFer (iron dextran) in mainland China. The deal grants CMS exclusive rights to two generations of intravenous iron products, both featuring single high-dose administration capabilities and strong reimbursement positioning in China's healthcare system.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65057#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65057"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65057#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System Secures Exclusive China Rights to Pharmacosmos&#8217; MonoFer and CosmoFer IV Iron Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65057"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65057\/revisions"}],"predecessor-version":[{"id":65059,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65057\/revisions\/65059"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}